After a 90% Gain, Is It Too Late to Buy Eli Lilly?
Eli Lilly's (NYSE: LLY) shares have soared over the past year, and for good reason. The drugmaker is a leader in one of the fastest-growing pharma segments today -- the weight-loss drug market. Eli Lilly sells Mounjaro, a type 2 diabetes drug that doctors also have prescribed for weight loss, and the company recently won approval for Zepbound specifically for weight management. Both drugs actually are the same molecule -- the GLP-1 agonist tirzepatide -- but sold under different brand names.
The big pharma company has a broad portfolio of drugs, spanning treatment areas from immunology to neurology, and a deep pipeline of candidates in development, some of which should drive future growth. Still, with shares up more than 90% over the past year and trading near their all-time high, is it too late to buy Eli Lilly stock?
Image source: Getty Images.
Source Fool.com
